Project Grant R33CA263703
Award Date
9/21/21
Completion Date
8/31/25
Dollars Obligated
$4.4M
Federal Agency
National Cancer Institute
Federal Grant Program
93.353
Assistance Type
Project Grant
Place of Performance
Santa Cruz, CA 95064, USA
Similar Awards
The National Cancer Institute (NCI) awarded a $1,019,013 Cooperative Agreement under the 21st Century Cures Act - Beau Biden Cancer Moonshot program (CFDA 93.353) to the Regents of the University of California, San Francisco (UCSF) to develop a Pre-Cancer Atlas of Skin Cancer. The overarching goal is to study the early stages of skin cancer development, including melanoma and cutaneous squamous cell carcinoma, and the role of the immune system in this transition from pre-cancer to cancer. The...
The President and Fellows of Harvard College, doing business as Harvard Medical School, was awarded a $4,597,818 project grant from the National Cancer Institute within the Department of Health and Human Services. The grant is funded under the 21st Century Cures Act - Beau Biden Cancer Moonshot program (CFDA 93.353), which supports cancer research initiatives. Under this award, Harvard Medical School will develop an integrative visualization framework for spatial single-cell cancer datasets...
This $1,069,188 Cooperative Agreement award, provided by the National Cancer Institute (NCI) under the 21st Century Cures Act - Beau Biden Cancer Moonshot program (CFDA 93.353), supports a collaborative research project to construct a comparative spatial atlas of low-grade gliomas. The research team from the University of California, Los Angeles (UCLA) Neurosurgery and the California Institute of Technology (Caltech) Spatial Single Cell team will expand on their preliminary data to generate an...
The National Cancer Institute (NCI) awarded a $877,856 Cooperative Agreement under the Cancer Biology Research (CFDA 93.396) program to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. to develop the Galaxy for Cancer (Galaxy-C) computational workbench. The goal is to create a platform that enables cancer researchers, especially those with limited computational skills, to more easily access, analyze, and extract insights from diverse cancer datasets and analysis tools....
The National Cancer Institute (NCI) awarded a $1,004,570 Cooperative Agreement under the 21st Century Cures Act - Beau Biden Cancer Moonshot (CFDA 93.353) program to The University of Texas MD Anderson Cancer Center (MD Anderson) for a 5-year project. The project aims to construct a 3D spatial atlas of high-grade serous ovarian cancer (HGSOC) to characterize tumor metastasis and the development of intrinsic chemotherapeutic resistance. The research team, comprised of experts from MD Anderson and...
This $1,131,820 Project Grant awarded by the National Cancer Institute (NCI) under the 21st Century Cures Act - Beau Biden Cancer Moonshot program (CFDA 93.353) will support research to characterize toxicities and health-related quality of life among diverse individuals receiving immune checkpoint inhibitors for metastatic cancer. The 5-year study, led by the University of Miami, aims to: 1) examine associations between patient characteristics and toxicities/quality of life, 2) identify...
The National Cancer Institute (NCI) awarded a $417,586 Project Grant (CFDA 93.396 - Cancer Biology Research) to The Broad Institute, Inc. to develop a "Platform for Multi-Modal Single Nucleus Spatial Genomics for Molecular Tumor Analysis." This 3-year project, commencing on August 1, 2024, aims to extend the institute's "Slide-Tags" single-cell spatial genomics technology to enable comprehensive profiling of human tumor samples. The project will integrate molecular, cellular,...
This Project Grant award from the National Cancer Institute (NCI), under the 21st Century Cures Act - Beau Biden Cancer Moonshot program (CFDA 93.353), provides $369,354.00 to The Regents of the University of California, San Francisco (UCSF) to conduct research on the tumor immune microenvironment and response to immunotherapy among different racial and ethnic populations with breast cancer. The key objectives of this research project are: 1) to determine how frequently women of different...
This federal Cooperative Agreement award, issued by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program, provides $416,745 to the University of Massachusetts Medical School (UMass Medical) to develop an Integrative Analysis and Visualization Platform for Cancer Regulatory Genomics. The project aims to: Create a Regulatory-Element-Target-Gene Atlas that enables researchers to explore connections between regulatory elements and cancer-associated...
This $1,128,990 Cooperative Agreement award from the National Cancer Institute (CFDA 93.353 - 21st Century Cures Act - Beau Biden Cancer Moonshot) will fund the Myeloma Multidimensional Precancer Atlas (MMPCA) project at the Dana-Farber Cancer Institute. The project aims to construct a comprehensive spatial and temporal atlas of precursor stages of multiple myeloma (MM) to understand genomic and microenvironmental alterations across the disease spectrum. Key objectives include: Mapping spatial...